Retrotope

19 articles about Retrotope

• Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

  10/19/2021

  Retrotope, today announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported in multiple oral presentations at the 2nd Annual Dry AMD Therapeutic Development Summit.

• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)

  10/6/2021

  Retrotope today reported data from its Phase 2/3 clinical trial of RT001 in patients with infantile neuroaxonal dystrophy (INAD) and its concurrent natural history study of disease onset and progression in INAD patients.

• 

  Retrotope Drug Improves Survival in Ultra-Rare Genetic Childhood Disease

  10/6/2021

  Retrotope cited data from its Phase II/III trial of RT001 in patients with infantile neuroaxonal dystrophy and reported on a natural history study of INAD patients’ disease onset and progression.

• Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)Target Enrollment for Study Surpassed in Less Than Six Weeks

  8/11/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, announced that enrollment has been completed for its multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with progressive supranuclear palsy.

• Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

  6/30/2021

  LOS ALTOS, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that the first patient has been dosed in a multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with progressive supranuclear palsy (PSP). Clinical investigators have already reported significant patient interest for participation i

• Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)Company Exceeds Target Enrollment in Less Than Six Weeks; Data Readout Expected by End of 2021

  4/21/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that enrollment has been completed for its multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

• Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

  3/17/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that the first patients have been dosed in a multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

• Retrotope to Present at H.C. Wainwright Global Life Sciences Conference

  3/3/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that Anil Kumar, president and chief business officer, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Sciences Conference.

• Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications

  2/25/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted two rare pediatric disease designations to RT001, the company’s lead development candidate.

• 

  BioSpace Movers & Shakers, Feb. 12

  2/12/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts

  2/11/2021

  Data Readout from Potentially Pivotal Phase 2/3 INAD Trial Expected 1H ‘01; Phase 2 ALS and Pivotal Phase 2/3 Friedreich’s Ataxia Trial Readouts Expected by Year-End

• US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

  2/18/2020

  Retrotope announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug for the treatment of Progressive SupraNuclear Palsy.

• Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)Three clinical trials centers now open for enrollment; two additional ones initiating

  1/9/2020

  Retrotope announced that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias.

• Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients

  10/4/2018

  Parkinson’s Institute and Clinical Center and Retrotope announced today a collaboration on a new drug therapy to treat patients with Progressive SupraNuclear Palsy.

• 

  FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (P...

  11/2/2017

  Physicians collaborating with Retrotope previously received approval from the FDA to test RT001 in Expanded Access trials of two patients having Infantile Neuroaxonal Dystrophy.

• Retrotope To Present First Human Data On Safety And Early Efficacy Of RT001 With Neurodegeneration At American Academy of Neurology Meeting

  4/25/2017

• Retrotope And Collaborators To Present Poster At American Academy of Neurology On Stabilized PUFA Drug Efficacy In Multiple Alzheimer’s Models

  4/25/2017

• Retrotope Announces Phase I/II Clinical Trial Results Of RT001 In Treatment Of Friedreich’s Ataxia

  9/16/2016